WO2008027600A3 - Imatinib compositions - Google Patents

Imatinib compositions Download PDF

Info

Publication number
WO2008027600A3
WO2008027600A3 PCT/US2007/019338 US2007019338W WO2008027600A3 WO 2008027600 A3 WO2008027600 A3 WO 2008027600A3 US 2007019338 W US2007019338 W US 2007019338W WO 2008027600 A3 WO2008027600 A3 WO 2008027600A3
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib
compositions
imatinib compositions
methods
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019338
Other languages
French (fr)
Other versions
WO2008027600A2 (en
Inventor
Iian Zalit
Boaz Pal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to CN2007800323449A priority Critical patent/CN101951889A/en
Priority to MX2009002336A priority patent/MX2009002336A/en
Priority to BRPI0715634-0A priority patent/BRPI0715634A2/en
Priority to US12/439,582 priority patent/US20090324718A1/en
Priority to CA002662265A priority patent/CA2662265A1/en
Priority to EP07811667A priority patent/EP2068835A2/en
Publication of WO2008027600A2 publication Critical patent/WO2008027600A2/en
Publication of WO2008027600A3 publication Critical patent/WO2008027600A3/en
Priority to IL197325A priority patent/IL197325A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Provided are compositions of imatinib, methods for their preparation, and methods for treatment using the same.
PCT/US2007/019338 2006-09-01 2007-09-04 Imatinib compositions Ceased WO2008027600A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2007800323449A CN101951889A (en) 2006-09-01 2007-09-04 Imatinib compositions
MX2009002336A MX2009002336A (en) 2006-09-01 2007-09-04 Imatinib compositions.
BRPI0715634-0A BRPI0715634A2 (en) 2006-09-01 2007-09-04 imatinib compositions
US12/439,582 US20090324718A1 (en) 2006-09-01 2007-09-04 Imatinib compositions
CA002662265A CA2662265A1 (en) 2006-09-01 2007-09-04 Imatinib compositions
EP07811667A EP2068835A2 (en) 2006-09-01 2007-09-04 Imatinib compositions
IL197325A IL197325A0 (en) 2006-09-01 2009-02-26 Imatinib compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84170706P 2006-09-01 2006-09-01
US60/841,707 2006-09-01

Publications (2)

Publication Number Publication Date
WO2008027600A2 WO2008027600A2 (en) 2008-03-06
WO2008027600A3 true WO2008027600A3 (en) 2008-04-24

Family

ID=38988059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019338 Ceased WO2008027600A2 (en) 2006-09-01 2007-09-04 Imatinib compositions

Country Status (8)

Country Link
US (1) US20090324718A1 (en)
EP (1) EP2068835A2 (en)
CN (1) CN101951889A (en)
BR (1) BRPI0715634A2 (en)
CA (1) CA2662265A1 (en)
IL (1) IL197325A0 (en)
MX (1) MX2009002336A (en)
WO (1) WO2008027600A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680249A1 (en) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories, Inc. Imatinib mesylate
EP2000139A1 (en) * 2007-06-07 2008-12-10 Novartis AG Stabilized amorphous forms of imatinib mesylate
CZ20098A3 (en) * 2009-01-13 2010-07-21 Zentiva, K.S. Medicinal forms of tyrosine kinase inhibitors
TR201010618A2 (en) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut An oral dosage form comprising imatinib and the manufacture of an oral dosage form
CN102552268A (en) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 Medicinal preparation containing crystal form a imatinib mesylate
PL394169A1 (en) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
WO2013008253A2 (en) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Imatinib formulations
CN102302464B (en) * 2011-08-04 2015-12-16 上海创诺制药有限公司 A kind of imatinib mesylate tablet
US20150125534A1 (en) 2011-11-24 2015-05-07 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
CN104367557A (en) * 2013-08-12 2015-02-25 浙江九洲药业股份有限公司 Preparation method of amorphous composition composed of drug active component and PVP
KR101778004B1 (en) * 2015-06-22 2017-09-15 (주) 에빅스젠 A Pharmaceutical Composition For Preventing and Treating Dry Eye Syndrome And Eye Disease With Dry Eye Syndrome Comprising Imatinib
CN107233325B (en) * 2017-06-23 2020-04-28 南京优科生物医药研究有限公司 A kind of composition containing imatinib and preparation method thereof
AU2020312840B2 (en) 2019-07-15 2026-01-22 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077892A2 (en) * 2002-03-15 2003-09-25 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
WO2003090720A1 (en) * 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
WO2006133046A2 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2003272548A1 (en) * 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
WO2004099186A1 (en) * 2003-05-06 2004-11-18 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
JP2008509144A (en) * 2004-08-04 2008-03-27 アルザ・コーポレーシヨン Sustained drug release composition exhibiting a rising zero-order release pattern, and a method for making such a composition
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
ATE445392T1 (en) * 2005-08-15 2009-10-15 Siegfried Generics Int Ag FILM TABLET OR GRANULES CONTAINING A PYRIDYLPYRIMIDINE
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077892A2 (en) * 2002-03-15 2003-09-25 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
WO2003090720A1 (en) * 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
WO2006133046A2 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations

Also Published As

Publication number Publication date
US20090324718A1 (en) 2009-12-31
IL197325A0 (en) 2009-12-24
MX2009002336A (en) 2009-03-20
WO2008027600A2 (en) 2008-03-06
EP2068835A2 (en) 2009-06-17
BRPI0715634A2 (en) 2013-07-02
CA2662265A1 (en) 2008-03-06
CN101951889A (en) 2011-01-19

Similar Documents

Publication Publication Date Title
WO2008027600A3 (en) Imatinib compositions
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2008034013A3 (en) Medical devices and methods of making the same
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2008005705A3 (en) Metal-containing formulations and methods of use
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2008121767A3 (en) Stitched polypeptides
WO2008054676A3 (en) Medical devices and methods of using the same
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008049116A3 (en) Substituted indoles
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
ZA201103036B (en) Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
IL200407A0 (en) Stable digestive enzyme compositions, methods of producing the same and uses thereof
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2009042114A3 (en) Phenazine derivatives and uses thereof
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2008017074A3 (en) Dyes and precursors and conjugates thereof
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780032344.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811667

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1220/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007811667

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 197325

Country of ref document: IL

Ref document number: 2009526760

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2662265

Country of ref document: CA

Ref document number: MX/A/2009/002336

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12439582

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0715634

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090220